This study sheds further light on mechanisms underlying the reduction of acute ischemic brain injury by CD8+ TRLs and the resulting functional recovery, thereby improving our mechanistic understanding of immunomodulation of stroke outcomes and accelerating breakthroughs against an intractable brain disorder that has defied effective treatment. This evidence concerns the gene CD8A and brain disorder.